BUHLMANN News

IBDoc® Talk #2 – Tips and Tricks Teleconference

Health Canada Licence: 98903, Device class: 3  BÜHLMANN IBDoc® is not available for sale in the US. IBDoc® is the first self-testing application for fecal calprotectin in IBD patients that involves three easy steps. IBDoc® allows IBD patients convenient self-testing of fecal calprotectin.  Learn, discuss, and share in another great discussion in IBDoc® Talk #2! Teleconference Overview Goal of Discussion
Continue Reading

Visit the BUHLMANN Booth at DDW 2019

Visit booth #842 to get an update on our Calprotectin and Therapeutic Drug Monitoring product portfolio: Quantum Blue® platform offering rapid and quantitative results for fecal calprotectin, serum calprotectin, CRP, serum infliximab trough levels, and serum adalimumab trough levels  (Additional trough level assays coming soon!)          US:Research Use Only. Not for use in diagnostic procedures in the US
Continue Reading

Protected: Basophils Are Still Alive

There is no excerpt because this is a protected post.

Continue Reading

Interview: BUHLMANN fCAL ELISA in a Clinical Laboratory- Expert User Perspectives

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared.  For in vitro Diagnostic Use. Health Canada License: 80726 In this Video You will Learn: Background information on calprotectin and it’s use in primary care Technical details of calprotectin testing in the laboratory Perspectives and general tips on the use of the BÜHLMANN fCAL® ELISA Contact our team and learn more about
Continue Reading

Connect with BUHLMANN at CDDW 2019!

Canadian Digestive Diseases Week (CDDW) 2019 BUHLMANN Diagnostics Corp Booth: #116 Mar 1 - 3, 2019 | Fairmont Banff Springs Hotel | Banff Alberta Learn More Visit our booth to get an update on our Calprotectin and Therapeutic Drug Monitoring product portfolio: IBDoc®, the ONLY in-vitro diagnostic POC and home testing device to measure the inflammatory marker, fecal
Continue Reading

BUHLMANN Diagnostics Corp Announces New Distribution Agreement with Meridian Biosciences, Inc.

BUHLMANN Diagnostic Corp (BDC), Amherst, NH is proud to announce they have entered into a distribution agreement with Meridian Bioscience, Inc., Cincinnati, Ohio to market the FDA-cleared BÜHLMANN fCAL® ELISA for the quantitative measurement of fecal calprotectin in human stool. The BÜHLMANN fCAL® ELISA aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn’s
Continue Reading

Two New fCAL turbo Video Testimonials from Portugal

BÜHLMANN fCAL® turbo is for Research Use Only in the US. Not to be used in diagnostic procedures. Health Canada License: 96808 Unilabs Portugal, a private European lab chain, made a comprehensive evaluation of different Calprotectin assays on the market and found many discrepancies with assays from other suppliers. Finally, they chose the BÜHLMANN fCAL® turbo simply because it
Continue Reading

Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring

IBDoc® Citation: Wei, S. , Tung, C. et al.  Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring. Intestinal Research 2018;16(4):546-553. DOI: https://doi.org/10.5217/ir.2018.00052 PMID: 30301339 Highlights from this Publication “96% of the patients were satisfied with the home test..." “71% of patients preferred the home test method monitor
Continue Reading

Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis

IBDoc® Citation: Walsh,  A,  Kormilitzin, A et al. Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis—a Prospective Analysis, Journal of Crohn's and Colitis, jjy184, PMID: 30445625   DOI: doi.org/10.1093/ecco-jcc/jjy184  Highlights from this Publication “This is the first prospective study to use validated endoscopic and histologic indices to determine the thresholds of
Continue Reading

IBDoc Canadian User Performance Evaluation

IBDoc® Citation: Alice C Moore, Vivian W Huang, Raymond Bourdages, Richard N Fedorak, Christian Reinhard, Yvette Leung, Brian Bressler, Greg Rosenfeld; IBDoc Canadian User Performance Evaluation, Inflammatory Bowel Diseases, , izy357, DOI: https://doi.org/10.1093/ibd/izy357 PMID: 30535387 Highlights from this Publication "The majority of patients found it easy-to-use and felt that most patients would be able to learn how to
Continue Reading